Price Disclosure Reductions for 2021 April Cycle
This summary only includes medicines taking a price disclosure reduction on 1 April 2021. The determined price disclosure outcomes for this cycle were calculated in accordance with the National Health Act 1953 (the Act) and National Health (Pharmaceutical Benefits) Regulations 2017 (the Regulations).
The outcomes below show percentage (%) price differences and ex‑manufacturer level prices. They do not include fees and mark-ups. Information about publication of prices including fees and mark-ups is set out below.
Flow-on Reductions for F2 Combination Items
Responsible persons with a brand of an F2 combination item should note that:
- if an F2 combination item is listed below, it has met the criteria for a direct reduction. However, this reduction may not take effect on 1 April 2021 if the price of a component ingredient is also reduced and flowing this component price on results in a lower price; or
- if an F2 combination item did not receive a direct price disclosure reduction, it may still receive a price reduction as a result of the flow-on of the price of a component ingredient that is taking a price disclosure reduction.
Outcomes for flow-on price disclosure reductions to F2 combination items have been communicated to responsible persons with brands of affected drugs in January 2021.
Legal Determination & Next Steps
The weighted average disclosed prices for each brand, including brands with a determination but no reduction, can be found in the legal determination on the Federal Register of Legislation website. Price disclosure reductions will apply to brands listed in Schedule 1 of the legal determination. Those brands in Schedule 2 of the determination will not take a price disclosure reduction because the percentage difference between their October 2020 PBS approved ex‑manufacturer price and the weighted average disclosed price was below 10% or 30% (as applicable and set out in the table below). Any new brands of existing pharmaceutical items with a determination in Schedule 1 that listed after 30 September 2020 will also take the reduction on 1 April 2021 under section 99ADHA of the Act.
An agreed process for responsible persons to raise any questions or concerns arising from an outcome mentioned above is set out in the Price Disclosure Dispute Resolution Administrative Process.
The date for lodgement of disputes was by 5:00pm AEDT on 8 January 2021.
Indicative prices for 1 April 2021 (including price to pharmacy, dispensed price for maximum quantity and price premiums) was published on 20 January 2021.
Final prices for 1 April 2021 reductions (including all price to pharmacy, dispensed price for maximum quantity/amount and price premiums) will be available from March 2021.
| Legal Instrument Drug (drugs marked with an * have a pharmaceutical item/s that met the 'no reduction' criteria) |
Legal Instrument Manner of Administrtaion (MoA) | Legal Instrument Form | Average AEMP ($) |
WAPD (%) across a drug/MoA |
WADP - April '21 PBS Price (AEMP) ($) per pharmaceutical item |
October '20 AEMP ($) |
Percentage difference between October '20 and April '21 PBS prices (AEMP) (%) per pharmaceutical item |
Calculations based on: OWAPD = all brand data GWAPD = originator brand data removed for at least one pharmaceutical item |
Applicable Unadjusted Price Reduction 10% or 30% |
|---|---|---|---|---|---|---|---|---|---|
| [Average AEMP minus WAPD = WADP] | [Difference between October '20 AEMP & WADP = % Difference] |
||||||||
| Anastrozole | Tablet 1 mg | Oral | 16.78 | 31.88 | 11.43 | 16.78 | 31.88% | GWAPD | 30 |
| Aripiprazole | Tablet 10 mg | Oral | 64.54 | 22.11 | 50.27 | 57.33 | 12.31% | GWAPD | 10 |
| Aripiprazole | Tablet 15 mg | Oral | 91.59 | 22.11 | 71.34 | 81.35 | 12.30% | GWAPD | 10 |
| Aripiprazole | Tablet 20 mg | Oral | 111.49 | 22.11 | 86.84 | 99.03 | 12.31% | GWAPD | 10 |
| Aripiprazole | Tablet 30 mg | Oral | 135.86 | 22.11 | 105.82 | 120.67 | 12.31% | GWAPD | 10 |
| Bivalirudin | Powder for I.V. injection 250 mg (as trifluoroacetate) | Injection | 474.81 | 12.83 | 413.89 | 474.81 | 12.83% | OWAPD | 10 |
| Bosentan | Tablet 125 mg (as monohydrate) | Oral | 1113.08 | 44.96 | 612.64 | 898.26 | 31.80% | GWAPD | 10 |
| Bosentan | Tablet 62.5 mg (as monohydrate) | Oral | 1113.08 | 44.96 | 612.64 | 898.26 | 31.80% | GWAPD | 10 |
| Cefuroxime* | Powder for oral suspension 125 mg (as axetil) per 5 mL, 70 mL | Oral | 8.00 | 15.13 | 6.79 | 8.00 | 15.13% | GWAPD | 10 |
| Cefuroxime* | Tablet 250 mg (as axetil) | Oral | 9.38 | 15.13 | 7.96 | 9.38 | 15.14% | GWAPD | 10 |
| Entecavir | Tablet 0.5 mg (as monohydrate) | Oral | 121.25 | 49.05 | 61.78 | 72.51 | 14.80% | GWAPD | 10 |
| Entecavir | Tablet 1 mg (as monohydrate) | Oral | 197.18 | 49.05 | 100.46 | 117.91 | 14.80% | GWAPD | 10 |
| Ezetimibe | Tablet 10 mg | Oral | 17.56 | 38.33 | 10.83 | 12.71 | 14.79% | Does not meet 30 month clock | 10 |
| Filgrastim* | Injection 300 micrograms in 0.5 mL single-use pre-filled syringe | Injection | 154.80 | 44.27 | 86.27 | 154.80 | 44.27% | GWAPD | 30 |
| Filgrastim* | Injection 480 micrograms in 0.5 mL single-use pre-filled syringe | Injection | 248.15 | 44.27 | 138.29 | 248.15 | 44.27% | GWAPD | 30 |
| Filgrastim* | Injection 480 micrograms in 1.6 mL | Injection | 496.31 | 44.27 | 276.59 | 496.31 | 44.27% | GWAPD | 30 |
| Ganciclovir | Powder for I.V. infusion 500 mg (as sodium) | Injection | 158.37 | 16.53 | 132.19 | 158.37 | 16.53% | Does not meet 30 month clock | 10 |
| Ibuprofen | Tablet 400 mg | Oral | 1.79 | 16.20 | 1.50 | 1.79 | 16.20% | GWAPD | 10 |
| Moxonidine | Tablet 200 micrograms | Oral | 7.10 | 10.39 | 6.36 | 7.10 | 10.42% | Does not meet 30 month clock | 10 |
| Moxonidine | Tablet 400 micrograms | Oral | 12.10 | 10.39 | 10.84 | 12.10 | 10.41% | Does not meet 30 month clock | 10 |
| Naloxone | Injection containing naloxone hydrochloride 2 mg in 2 mL pre-filled syringe | Injection | 27.77 | 19.74 | 22.29 | 27.77 | 19.73% | OWAPD | 10 |
| Naloxone | Injection containing naloxone hydrochloride 400 micrograms in 1 mL ampoule | Injection | 31.49 | 19.74 | 25.27 | 31.49 | 19.75% | OWAPD | 10 |
| Nortriptyline | Tablet 10 mg (as hydrochloride) | Oral | 4.45 | 20.22 | 3.55 | 4.45 | 20.22% | GWAPD | 10 |
| Nortriptyline | Tablet 25 mg (as hydrochloride) | Oral | 5.60 | 20.36 | 4.46 | 5.60 | 20.36% | GWAPD | 10 |
| Olmesartan with amlodipine | Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate) | Oral | 4.66 | 11.70 | 4.11 | 4.66 | 11.80% | OWAPD | 10 |
| Olmesartan with amlodipine | Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) | Oral | 9.60 | 11.70 | 8.48 | 9.60 | 11.67% | OWAPD | 10 |
| Olmesartan with amlodipine | Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) | Oral | 8.96 | 11.70 | 7.91 | 8.96 | 11.72% | OWAPD | 10 |
| Pegfilgrastim | Injection 6 mg in 0.6 mL single use pre-filled syringe | Injection | 1175.00 | 70.52 | 346.39 | 934.95 | 62.95% | GWAPD | 10 |
| Pregabalin | Capsule 150 mg | Oral | 24.02 | 39.77 | 14.47 | 18.42 | 21.44% | GWAPD | 10 |
| Pregabalin | Capsule 25 mg | Oral | 7.08 | 39.77 | 4.26 | 5.43 | 21.55% | GWAPD | 10 |
| Pregabalin | Capsule 300 mg | Oral | 35.84 | 39.77 | 21.59 | 27.48 | 21.43% | GWAPD | 10 |
| Pregabalin | Capsule 75 mg | Oral | 15.66 | 39.77 | 9.43 | 12.01 | 21.48% | GWAPD | 10 |
| Raloxifene | Tablet containing raloxifene hydrochloride 60 mg | Oral | 27.35 | 30.10 | 19.12 | 27.35 | 30.09% | GWAPD | 30 |
| Rituximab | Solution for I.V. infusion 100 mg in 10 mL | Injection | 479.73 | 35.27 | 310.53 | 388.87 | 20.15% | Does not meet 30 month clock | 10 |
| Rituximab | Solution for I.V. infusion 500 mg in 50 mL | Injection | 1199.32 | 35.27 | 776.32 | 972.17 | 20.15% | Does not meet 30 month clock | 10 |
| Rituximab | Solution for subcutaneous injection containing rituximab 1400 mg in 11.7 mL | Injection | 1699.12 | 35.27 | 1099.84 | 1699.12 | 35.27% | Does not meet 30 month clock | 10 |
| Rosuvastatin* | Tablet 20 mg (as calcium) | Oral | 5.11 | 30.62 | 3.55 | 5.11 | 30.53% | GWAPD | 30 |
| Rosuvastatin* | Tablet 40 mg (as calcium) | Oral | 7.30 | 30.62 | 5.06 | 7.30 | 30.68% | GWAPD | 30 |
| Rosuvastatin* | Tablet 5 mg (as calcium) | Oral | 2.45 | 30.62 | 1.70 | 2.45 | 30.61% | GWAPD | 30 |
| Sevelamer | Tablet containing sevelamer carbonate 800 mg | Oral | 198.79 | 10.84 | 177.24 | 198.79 | 10.84% | Does not meet 30 month clock | 10 |
| Sevelamer | Tablet containing sevelamer hydrochloride 800 mg | Oral | 198.79 | 10.84 | 177.24 | 198.79 | 10.84% | Does not meet 30 month clock | 10 |
| Tenofovir | Tablet containing tenofovir disoproxil fumarate 300 mg | Oral | 339.37 | 41.95 | 197.00 | 298.88 | 34.09% | GWAPD | 10 |
| Tenofovir | Tablet containing tenofovir disoproxil maleate 300 mg | Oral | 339.37 | 41.95 | 197.00 | 298.88 | 34.09% | GWAPD | 10 |
| Tenofovir | Tablet containing tenofovir disoproxil phosphate 291 mg | Oral | 339.37 | 41.95 | 197.00 | 298.88 | 34.09% | GWAPD | 10 |
| Tenofovir with emtricitabine | Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg | Oral | 92.49 | 41.82 | 53.81 | 92.49 | 41.82% | OWAPD | 10 |
| Tenofovir with emtricitabine | Tablet containing tenofovir disoproxil maleate 300 mg with emtricitabine 200 mg | Oral | 92.49 | 41.82 | 53.81 | 92.49 | 41.82% | OWAPD | 10 |
| Tenofovir with emtricitabine | Tablet containing tenofovir disoproxil phosphate 291 mg with emtricitabine 200 mg | Oral | 92.49 | 41.82 | 53.81 | 92.49 | 41.82% | OWAPD | 10 |
| Tranexamic acid | Tablet 500 mg | Oral | 27.14 | 12.16 | 23.84 | 27.14 | 12.16% | GWAPD | 10 |
| Trastuzumab* | Powder for I.V. infusion 150 mg | Injection | 533.22 | 20.17 | 375.39 | 470.25 | 20.17% | Does not meet 30 month clock | 10 |
| Trastuzumab* | Powder for I.V. infusion 420 mg | Injection | 1493.02 | 20.17 | 1057.09 | 1316.69 | 20.17% | Does not meet 30 month clock | 10 |
| Trastuzumab* | Powder for I.V. infusion 60 mg | Injection | 213.29 | 20.17 | 150.16 | 188.10 | 20.17% | Does not meet 30 month clock | 10 |
| Valganciclovir | Tablet 450 mg (as hydrochloride) | Oral | 713.52 | 23.23 | 547.77 | 713.52 | 23.23% | GWAPD | 10 |
Confirmed prices of brands scheduled for a price disclosure reduction
The Confirmed Prices Report outlines the approved ex-manufacturer prices for brands scheduled to take a price disclosure reduction. The reports for the 2021 April cycle can be downloaded below.